Curković Bozidar
Klinika za reumatske bolesti i rehabilitaciju Medicinskoga fakulteta Sveucilista u Zagrebu Klinicki bolnicki centar Zagreb, Kispatićeva 12, 10000 Zagreb.
Reumatizam. 2003;50(2):49-50.
Bisphosphonates (risedronate and alendronate) inhibit bone resorption, increase bone mass and reduce the risk of vertebral and nonvertebral fractures in postmenopausal women as has been shown in a number of clinical trials. The concept of bone quality has recently been actualized with evidence that antiresorptive drugs reduce the occurrence of fractures to a greater extent than would be predicted by the amount of the increase in bone density. Concern about possible negative effect on fracture resistance with prolonged treatment with bisphosphonates has no evidence from clinical studies. Both preclinical and clinical studies, histologically and biomechanically performed, have revealed normal quality of bone formed during treatment with bisphosphonates.
双膦酸盐类药物（利塞膦酸盐和阿仑膦酸盐）可抑制骨吸收，增加骨量，并降低绝经后女性发生椎体和非椎体骨折的风险，多项临床试验已证实这一点。最近，骨质量的概念得到了进一步证实，有证据表明，抗吸收药物降低骨折发生率的程度大于骨密度增加量所预测的程度。关于双膦酸盐类药物长期治疗可能对骨折抵抗力产生负面影响的担忧，目前尚无临床研究证据。临床前和临床研究，无论是从组织学还是生物力学角度进行的，均显示双膦酸盐类药物治疗期间形成的骨质量正常。
